Tags

Type your tag names separated by a space and hit enter

Immunogenicity and safety of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine: a systematic review.
Infect Dis Poverty. 2022 May 13; 11(1):53.ID

Abstract

BACKGROUND

Heterologous prime-boost with ChAdOx1 nCoV-19 vector vaccine (ChAd) and a messenger RNA vaccine (BNT or mRNA-1273) has been widely facilitating mass coronavirus disease 2019 (COVID-19) immunisation. This review aimed to synthesize immunogenicity and reactogenicity of heterologous immunisations with ChAd and BNT (mRNA-1273) vaccine compared with homologous ChAd or BNT (mRNA-1273) immunisation.

METHODS

PubMed, Web of Science, and Embase databases were searched from inception to March 7, 2022. Immunogenicity involving serum antibodies against different SAS-CoV-2 fragments, neutralizing antibody, or spike-specific T cells response were compared. Any, local and systemic reactions were pooled by meta-analysis for comparison.

RESULTS

Of 14,571 records identified, 13 studies (3024 participants) were included for analysis. Compared with homologous BNT/BNT vaccination, heterologous ChAd/BNT schedule probably induced noninferior anti-spike protein while higher neutralizing antibody and better T cells response. Heterologous ChAd/BNT (mRNA-1273) immunisation induced superior anti-spike protein and higher neutralizing antibody and better T cells response compared with homologous ChAd/ChAd vaccination. Heterologous ChAd/BNT (mRNA-1273) had similar risk of any reaction (RR = 1.30, 95% CI: 0.86-1.96) while higher risk of local reactions (RR = 1.65, 95% CI: 1.27-2.15) and systemic reactions (RR = 1.49, 95% CI: 1.17-1.90) compared with homologous ChAd/ChAd vaccination. There was a higher risk of local reactions (RR = 1.16, 95% CI: 1.03-1.31) in heterologous ChAd/BNT (mRNA-1273) vaccination compare with homologous BNT/BNT but a similar risk of any reaction (RR = 1.03, 95% CI: 0.79-1.34) and systemic reactions (RR = 0.89, 95% CI: 0.60-1.30).

CONCLUSIONS

Heterologous ChAd/BNT schedule induced at least comparable immunogenicity compared with homologous BNT/BNT and better immunogenicity compared with homologous ChAd/ChAd vaccination. The synthetical evidence supported the general application of heterologous prime-boost vaccination using ChAd and BNT COVID-19 vaccines.

Authors+Show Affiliations

Expanded Program Immunization Division of Shandong Provincial Center for Disease Control and Prevention, Shandong Provincial Key Laboratory of Infectious Disease Control and Prevention, Jinan, 250014, China.Nosocomial Infection Control Department, Shenzhen University General Hospital, Shenzhen, 518071, China.Clinical Research Academy, Peking University Shenzhen Hospital, Peking University, Shenzhen, 518036, China.School of Public Health, Shenzhen University Health Science Center, No. 1066 Xueyuan Avenue, Shenzhen, 518060, China. liujiaye1984@163.com.

Pub Type(s)

Journal Article
Meta-Analysis
Review
Systematic Review

Language

eng

PubMed ID

35562753

Citation

Lv, Jingjing, et al. "Immunogenicity and Safety of Heterologous Versus Homologous Prime-boost Schedules With an Adenoviral Vectored and mRNA COVID-19 Vaccine: a Systematic Review." Infectious Diseases of Poverty, vol. 11, no. 1, 2022, p. 53.
Lv J, Wu H, Xu J, et al. Immunogenicity and safety of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine: a systematic review. Infect Dis Poverty. 2022;11(1):53.
Lv, J., Wu, H., Xu, J., & Liu, J. (2022). Immunogenicity and safety of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine: a systematic review. Infectious Diseases of Poverty, 11(1), 53. https://doi.org/10.1186/s40249-022-00977-x
Lv J, et al. Immunogenicity and Safety of Heterologous Versus Homologous Prime-boost Schedules With an Adenoviral Vectored and mRNA COVID-19 Vaccine: a Systematic Review. Infect Dis Poverty. 2022 May 13;11(1):53. PubMed PMID: 35562753.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Immunogenicity and safety of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine: a systematic review. AU - Lv,Jingjing, AU - Wu,Hui, AU - Xu,Junjie, AU - Liu,Jiaye, Y1 - 2022/05/13/ PY - 2022/02/09/received PY - 2022/04/18/accepted PY - 2022/5/13/entrez PY - 2022/5/14/pubmed PY - 2022/5/18/medline KW - COVID-19 KW - Heterologous vaccination KW - Homologous vaccination KW - Immunogenicity KW - Safety SP - 53 EP - 53 JF - Infectious diseases of poverty JO - Infect Dis Poverty VL - 11 IS - 1 N2 - BACKGROUND: Heterologous prime-boost with ChAdOx1 nCoV-19 vector vaccine (ChAd) and a messenger RNA vaccine (BNT or mRNA-1273) has been widely facilitating mass coronavirus disease 2019 (COVID-19) immunisation. This review aimed to synthesize immunogenicity and reactogenicity of heterologous immunisations with ChAd and BNT (mRNA-1273) vaccine compared with homologous ChAd or BNT (mRNA-1273) immunisation. METHODS: PubMed, Web of Science, and Embase databases were searched from inception to March 7, 2022. Immunogenicity involving serum antibodies against different SAS-CoV-2 fragments, neutralizing antibody, or spike-specific T cells response were compared. Any, local and systemic reactions were pooled by meta-analysis for comparison. RESULTS: Of 14,571 records identified, 13 studies (3024 participants) were included for analysis. Compared with homologous BNT/BNT vaccination, heterologous ChAd/BNT schedule probably induced noninferior anti-spike protein while higher neutralizing antibody and better T cells response. Heterologous ChAd/BNT (mRNA-1273) immunisation induced superior anti-spike protein and higher neutralizing antibody and better T cells response compared with homologous ChAd/ChAd vaccination. Heterologous ChAd/BNT (mRNA-1273) had similar risk of any reaction (RR = 1.30, 95% CI: 0.86-1.96) while higher risk of local reactions (RR = 1.65, 95% CI: 1.27-2.15) and systemic reactions (RR = 1.49, 95% CI: 1.17-1.90) compared with homologous ChAd/ChAd vaccination. There was a higher risk of local reactions (RR = 1.16, 95% CI: 1.03-1.31) in heterologous ChAd/BNT (mRNA-1273) vaccination compare with homologous BNT/BNT but a similar risk of any reaction (RR = 1.03, 95% CI: 0.79-1.34) and systemic reactions (RR = 0.89, 95% CI: 0.60-1.30). CONCLUSIONS: Heterologous ChAd/BNT schedule induced at least comparable immunogenicity compared with homologous BNT/BNT and better immunogenicity compared with homologous ChAd/ChAd vaccination. The synthetical evidence supported the general application of heterologous prime-boost vaccination using ChAd and BNT COVID-19 vaccines. SN - 2049-9957 UR - https://www.unboundmedicine.com/medline/citation/35562753/Immunogenicity_and_safety_of_heterologous_versus_homologous_prime_boost_schedules_with_an_adenoviral_vectored_and_mRNA_COVID_19_vaccine:_a_systematic_review_ DB - PRIME DP - Unbound Medicine ER -